Clene Inc. (NASDAQ: CLNN) VISIONARY-MS Trial Data May

New Post Public Reply Private Reply Replies (0) Message Board
NetworkNewsWire
235
Clene Inc. (NASDAQ: CLNN) VISIONARY-MS Trial Data May Support CNM-Au8(R) as Long-Sought-After Multiple Sclerosis Treatment

- Significant improvements in both vision and cognition, sustained over three years, were reported with CNM-Au8 treatment in results from the long-term open-label extension (“LTE”) of the VISIONARY-MS trial in participants with stable relapsing multiple sclerosis
- Michael Barnett, a key clinical advisor, hailed the results, observed long term and over and above background therapy. as “unprecedented”
- A drug that may halt MS disease progression or improve function on top of standard-of-care MS therapies would represent a significant milestone in drug development for this disease
- Clene will present the full clinical results for the LTE at the ninth annual Americas Committee for Treatment and Research in Multiple Sclerosis Forum scheduled for February 29 through March 2, 2024, in West Palm Beach, Florida

Clene (NASDAQ: CLNN) and its wholly-owned subsidiary Clene Nanomedicine Inc., is a clinical-stage biopharmaceutical company focused on improving mitochondrial health and protecting neuronal function to treat neurodegenerative diseases, including amyotrophic lateral sclerosis (“ALS”) and multiple sclerosis (“MS”). The company recently reported new CNM-Au8(R) results from a long-term open-label extension (“LTE”) of the VISIONARY-MS trial in participants with stable relapsing multiple sclerosis (“RMS”) totaling nearly three years of follow-up (https://nnw.fm/tERfF ).

Clene is closely studying CNM-Au8 because a drug that may halt MS disease progression and may even improve function on top of standard-of-care MS therapies would represent a milestone achievement in drug development for this disease.

After completing the double-blind period, study participants were offered continuance of CNM-Au8 30mg for up to an additional 96 weeks in the LTE. Analyses were reported for the modified intent to treat population that included all study participants with valid clinical data. Clene noted that:

Low contrast vision acuity (“LCVA”) demonstrated sustained improvement by up to 38 letters across both eyes in individual participants, representing multiple row gains on a greyed-out MS eye chart.
Cognitive improvement, particularly working memory and information processing speed as tested using the symbol digit modality test (“SDMT”), showed improvement by up to 35 points in individual participants, where a three-point change in cognitive processing speed has been deemed notable in other MS studies.
Improvements demonstrated during the 48-week double-blind period were sustained in the LTE for the timed 25-foot walk and nine-hole peg tests.

CNM-Au8 is used in combination with other agents, has no known drug-drug interactions, and is designed to improve function in MS.

Clinical effects improving both function and survival were seen in an earlier ALS trial, using the same drug.

Professor Michael Barnett, Professor of Neurology, Brain and Mind Centre, University of Sydney, and one of the trial’s key clinical advisors, said, the observed long-term clinical improvements for participants with stable disease, over and above background immunomodulatory disease-modifying therapy, are unprecedented. “The data show clear overall improvements in vision and cognition for participants treated for nearly three years from randomization. Importantly, these results were robust and consistent,” Barnett added. “Positive impacts on disease progression and the potential to at least partially reverse established disability, if confirmed in a larger study, represent a major therapeutic leap for patients with MS.”

Placebo participants who transitioned to CNM-Au8 during the LTE showed significant improvements compared to the original baseline in LCLA and SDMT, generally consistent with the increase observed in participants originally randomized to Clene’s lead asset.

Dr. Benjamin Greenberg, M.D., Head of Medicine at Clene, underscored the idea that despite tremendous advances in immunotherapies for MS, there is a significant unmet need for treatments to prevent neurodegeneration and create opportunities for clinical improvement. “These data continue to build a strong case in favor of pursuing CNM-Au8 in upcoming Phase 3 studies. Clinically significant improvement is rarely seen in MS patients, and this trial provides evidence of CNM-Au8’s potential to improve function in this population,” Greenberg said. “Clene is currently reviewing these data with prospective pharmaceutical partners interested in MS.”

Clene will present the full clinical results for the LTE at the ninth annual Americas Committee for Treatment and Research in Multiple Sclerosis (“ACTRIMS”) Forum scheduled for February 29 through March 2, 2024, in West Palm Beach, Florida.

For more information, visit the company’s website at www.Clene.com.

NOTE TO INVESTORS: The latest news and updates relating to CLNN are available in the company’s newsroom at https://nnw.fm/CLNN

Please see full terms of use and disclaimers on the NetworkNewsWire website applicable to all content provided by NNW, wherever published or re-published: http://NNW.fm/Disclaimer


Clene Inc. (CLNN) Stock Research Links

CLNN Board Company Profile Buy Rating Time & Sales News Filings Financials
Scroll down for more posts ▼

Top 10 Most Recent News Articles

Six LIFE Photographers Bring History Into Florida Focus

Updated Category News Views 0

Seventy photographs can make a pretty loud argument when the historical record has been this lopsided. The Ashley Gibson Barnett Museum of Art at Florida Southern College has brought LIFE: Six Women Photographers to Lakeland, and it deserves more than the usual polite nod given to a traveling museum show. Open since November 14, 2026, and running through March 7, 2027,...

Continue Reading
GreenTree Faces Softer Rooms, Debt and NYSE Deadline

Updated Category News Views 34

A hotel operator can post positive earnings and still leave shareholders with a nasty headache, and GreenTree's third quarter is that kind of report. NYSE:GHG produced RMB243.0 million in revenue, down 22.2% from a year earlier, while net income slipped to RMB49.3 million from RMB59.0 million. This was not a one-line stumble. Room pricing, occupancy, franchise economics...

Continue Reading
Point72 Breach Puts Cyber Controls Under the Microscope

Updated Category News Views 138

Two compromised user accounts can turn a supposedly contained cyber problem into a boardroom headache in a hurry. Point72 Asset Management, the global alternative-investment firm founded by Steven A. Cohen in 2014, has reported a social-engineering incident involving accounts that were used to copy files from limited portions of its IT systems. This is not a trading-loss...

Continue Reading
Danaher and Microsoft Put AI Into the Lab Stack Early

Updated Category News Views 39

Laboratory AI gets interesting only when it reaches the hardware bench, and Danaher is taking a serious swing at that ugly, complicated job with Microsoft. The Nov. 20 partnership is not just another chatbot bolted onto a dashboard. It is aimed at building a common agentic platform that can help instruments interpret scientific intent, guide setup, control hardware within...

Continue Reading
Swim Readiness Depends on Skills, Not Birthdays Alone

Updated Category News Views 23

A child popping up calmly after a brief dunk tells you more than a birthday ever will. That is the sensible center of Woody Alpern's guidance for families weighing whether a child belongs in the next swim level. The Atlanta swim school expert's point is refreshingly free of the usual parental race: advancement is earned through repeatable skills, comfort, and judgment in...

Continue Reading
Worker Pullback Is a Cost Problem Employers Ignore

Updated Category News Views 13

Somewhere between a job description and an unpaid favor, a lot of corporate productivity appears to be quietly leaking out. MyPerfectResume’s July 2026 survey of 1,000 U.S. workers says 78% have intentionally done only the minimum needed to keep their jobs at least once. That is not a cute workplace-culture headline. It is a warning flare about discretionary...

Continue Reading
Sleep Number’s Couples Pitch Has Some Fine Print Too

Updated Category News Views 52

A thermostat war in the bedroom is a lousy reason to buy the wrong mattress. Yet that is the mundane, very real problem Sleep Number is leaning into after Expert Consumers named it a leading 2026 choice for couples seeking personalized sleep comfort. The company’s argument is straightforward: two people sharing a bed should not have to share one firmness setting, or...

Continue Reading
FFR Adds Academic and Commercial Muscle to Its Board

Updated Category News Views 65

Robotics boards can get crowded with lofty nouns fast, and FFR just added another one with some real-world connective tissue behind it. Carolyn Kissane, associate dean at NYU's Center for Global Affairs, has joined as an independent director. The appointment is not a product launch, a contract, or revenue. It is a governance move. Still, in a business trying to weld...

Continue Reading
Chargeback AI Still Has a Costly Last-Mile Problem

Updated Category News Views 41

A corrected headline is a small wrinkle, but the underlying chargeback mess is not. Chargeflow and Juniper Research surveyed 121 senior executives at U.S. and U.K. businesses with at least $100 million in annual gross merchandise value, and the useful takeaway is painfully clear: merchants are putting AI on the label without rebuilding the machinery underneath. That...

Continue Reading
North Richland Hills Bets on Its Visitor Momentum Now

Updated Category News Views 49

A crowded family attraction map is a nice problem for a Texas city to have, and North Richland Hills is trying to turn that pile of assets into a cleaner regional tourism machine. On Nov. 20, 2026, the city introduced “The Place You Never Outgrow,” its first destination-marketing campaign, built with Flat Five Marketing. This is not a stock story in the usual...

Continue Reading

Top 5 Most Recently Viewed Articles

Garanti BBVA Partners with Ripple and IBM for Secure Crypto Trading

Updated Category News Views 110

Garanti BBVA's Strategic Collaboration Garanti BBVA Kripto has formed a partnership with Ripple and IBM to enhance its digital asset trading platform, prioritizing security and performance. After a pilot phase that showcased effective technology integration, the bank is set to expand the offering to its full customer base, assuring its commitment to top-tier financial...

Continue Reading
Understanding Current Market Sentiment Amidst Tariff Concerns

Updated Category News Views 469

Market Sentiment and Tariffs' Influence Recently, there has been a noticeable shift in market sentiment, reflecting a more bearish outlook. Investors are understandably concerned about the impeding implications of tariffs and their impact on economic growth. This situation invites a closer examination of how sentiment plays a crucial role in market trends and potential...

Continue Reading
Marriott International Announces Exciting New Ritz-Carlton Hotel

Updated Category News Views 254

Marriott International Expands to Xiamen with The Ritz-Carlton Marriott International, Inc. has recently made a significant move in the hospitality sector by entering into an agreement with Xiamen Green Development Investment Group to introduce The Ritz-Carlton brand to Xiamen Island. This expansion showcases Marriott's commitment to delivering luxury services paired with...

Continue Reading
Jencap Shines in Insurance Leadership, Gains Recognition

Updated Category News Views 34

Breaking Down Jencap's Accolade In a crowded insurance landscape, getting noticed is no small feat. Well, Jencap just nabbed a recognition that places it in the industry's spotlight. According to Insurance Business America's latest annual report, Jencap shines as a 5-Star Program Administrator. This recognition didn’t just fall into their lap; it’s a nod that industry...

Continue Reading
Global Insights into the Air Quality Control Systems Market

Updated Category News Views 329

Understanding the Air Quality Control Systems Market The air quality control systems (AQCS) market is experiencing significant growth and is projected to reach a remarkable valuation of $195.1 billion by 2032. As reported, the market had a value of $105.2 billion in 2023, showing a promising compound annual growth rate (CAGR) of 6.8% during the period from 2024 to 2032....

Continue Reading